Paul Hastings LLP represented BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a pharmaceutical company that develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions, in connection with its underwritten public offering of 1,500,000 shares of common stock. BioMarin estimated the offering would raise gross proceeds of approximately $119.3 million before costs.

BofA Merrill Lynch acted as underwriter for the offering.

Securities & Capital Markets partner Thomas Pollock led the Paul Hastings team, which also included corporate associates Samantha Eldredge and Aliza Cohen.

Paul Hastings has also advised BioMarin in a $750 million offering in November 2013 and a $249 million offering in June 2012.